Latest News & Updates

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
September 12, 2024

Continue Reading »

Prescription for Change: Doctors Cast Their Votes for a Healthier Future
August 28, 2024

Continue Reading »

Centers for Medicare & Medicaid Services (CMS) Releases the First Ten Drug Prices Negotiated in IRA Process for Part D
August 28, 2024

Continue Reading »

Merit-based Incentive Payment System (MIPS) Automatic Extreme and Uncontrollable Circumstances (EUC) Policy Applied to MIPS Eligible Clinicians in Florida
August 28, 2024

Continue Reading »

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma
September 18, 2024

Continue Reading »

FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara Co-Pack for early high-risk breast cancer
September 18, 2024

Continue Reading »

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
September 12, 2024

Continue Reading »

FDA approves lazertinib with amivantamab-vmjw for non-small lung cancer
August 20, 2024

Continue Reading »

Get More from FLASCO With Your Partnership

The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Partners

Diamond Elite

Diamond

Platinum

Gold

Upcoming Events

Click to view full events calendar.

October 17, 2024 5:30 pm
LGBTQIA+ Living With Cancer
November 1, 2024
2024 FLASCO Fall Session

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: